GRI Bio, Inc. (GRI:NASDAQ) closed at $1.45 on October 23, 2026, up 1.40% on the day. The stock trades 97.7% below its 52-week high of $64.12 and 6.6% above its 52-week low of $1.36. Over the past year, it lost 97.5%. GRI Bio, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, GRI closed higher on 109 days (43%). Its best day was August 11, 2026 (+29.41%) and its worst was December 11, 2025 (-56.45%). The stock moved 10% or more in a single session 33 times. It opened at least 5% above the previous day's high 1 time.
Vallon Pharmaceuticals Inc is a biopharmaceutical company, which focuses on the development and commercialization of proprietary biopharmaceutical products. The company develops prescription drugs for central nervous system disorders. Its product ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder, and narcolepsy.
Find more stocks like GRI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.